52-year-old female with stage IV breast cancer, 5 months status-post left modified radical mastectomy, with no prior history of cardiovascular disease.
5th cycle of chemotherapy with doxorubicin and cyclophosphamide.
Development of non-ST elevation myocardial infarction (NSTEMI) and supraventricular tachycardia (SVT) with aberrancy.
This case highlights the rare occurrence of chemotherapy-induced NSTEMI and SVT with aberrancy following doxorubicin and cyclophosphamide treatment, emphasizing the need for vigilant cardiac monitoring.
Chemotherapy-induced myocardial infarction (MI) is an exceptionally rare but significant complication of cancer treatment. This report discusses a case of a 52-year-old patient with breast cancer who developed non-ST elevation myocardial infarction (NSTEMI) three days after receiving doxorubicin and cyclophosphamide that were her 5th cycle of chemotherapy. The diagnosis was supported by elevated troponin levels, echocardiographic findings, and electrocardiography (ECG) showing supraventricular tachycardia (SVT) with aberrancy, which was treated with cardioversion. This case highlights the importance of distinguishing chemotherapy-induced MI from other cardiotoxic effects and emphasizes the need for vigilant cardiac monitoring during cancer therapy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Eilham Elias Jobir
Merahi Kefyalew Merahi
Kefelegn Negalign Mekuria
International Journal of Emergency Medicine
Addis Ababa University
Dilla University
Wolkite University
Building similarity graph...
Analyzing shared references across papers
Loading...
Jobir et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69edabdf4a46254e215b3aaf — DOI: https://doi.org/10.1186/s12245-026-01238-6